Skip to content

Discontinued — last reported Q4 '22

Total Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$11.49B+2.6%
Amgen logo
AmgenAMGN
$8.62B+5.8%
Gilead Sciences logo
Gilead SciencesGILD
$6.96B+4.4%
CG Oncology logo
CG OncologyCGON
$1.08M+1,983%
Immunome logo
ImmunomeIMNM
$0-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$17M-39.3%

Other financials

Income statement

See full
Operating income-$16.3M-100%
Net income-$8.9M-220%
EPS (diluted)-$0.14-208%

Balance sheet

See full
Cash & equivalents$194.8M+111%
Total debt$2.8M-73.9%
Total equity$138.0M+84.8%
Total assets$201.9M+111%

Cash flow

See full
Operating cash flow-$18.0M-109%
CapEx$675.0K+22,400%
Free cash flow-$18.7M-117%

Valuation

See full
Market cap$693.87M+192%
Enterprise value$501.88M+220%
P/S5,595.7×-18,674×

Profitability

See full
Operating margin-28,000.8%+15,050pp
Net margin-15,156.5%-5,064pp
FCF margin-26,383.9%+14,851pp

Returns & leverage

See full
Return on equity-51.2%-16.6pp
Debt / equity-0.1×
Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Candel Therapeutics, Inc.’s 10-K, filed March 28, 2024, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s total revenue?
Candel Therapeutics, Inc. (CADL) reported total revenue of $31K in Q4 2022.
How has Candel Therapeutics, Inc.'s total revenue changed year-over-year?
Candel Therapeutics, Inc.'s total revenue decreased by 0.0% year-over-year, from $31K to $31K.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.